Gut Bacterial Compound ImP Linked to Increased Alzheimer's Risk and Cognitive Decline
A recent study has revealed that a molecule produced by gut bacteria, known as imidazole propionate (ImP), may increase the risk of Alzheimer's disease and contribute to cognitive decline in individuals with dementia. This finding could pave the way for new treatment strategies aimed at lowering the risk of Alzheimer's. Nearly ten years ago, a research team from the University of Wisconsin-Madison, led by professors Barbara Bendlin and Federico Rey, discovered that the gut microbiome composition differs significantly between individuals with Alzheimer's disease and those who are healthy. Since then, they have been investigating how these differences in gut bacteria may influence brain health.
In their latest study, published in Nature Communications, the researchers focused on ImP, a compound produced by certain gut bacteria. Their findings suggest that ImP may play a role in brain changes associated with Alzheimer's disease and other forms of dementia. The production of ImP varies widely among individuals; some produce it in larger quantities while others produce little. Rey noted that while ImP-producing bacteria are present in many people, they are not necessarily abundant, yet their impact on the host can be significant.
Once synthesized in the gut, ImP can enter the bloodstream and affect other areas of the body. Previous studies have linked this compound to conditions such as type 2 diabetes and coronary artery disease. The new research indicates that ImP may also influence brain health. In experiments conducted on mice, the researchers observed that ImP entering the brain led to an increase in the accumulation of beta amyloid and tau proteins, both of which are key indicators of Alzheimer's disease. This accumulation is associated with neuronal death, a hallmark of Alzheimer's.
The team analyzed blood samples from nearly 1,200 participants in the Wisconsin Registry for Alzheimer's Prevention and other studies associated with the Wisconsin Alzheimer's Disease Research Center. They found that individuals with elevated ImP levels in their blood were significantly more likely to exhibit biological markers linked to abnormal protein accumulation and impaired neuronal function characteristic of dementia. Notably, cognitive testing revealed that those with higher ImP levels experienced a more rapid decline in cognitive abilities over time.
Additionally, the researchers identified a genetic variation that correlates with higher ImP levels in the bloodstream, affecting approximately 43% of study participants. This genetic factor may influence how effectively the kidneys eliminate ImP from the blood, thereby impacting its concentration in circulation. Rey pointed out that this genetic variation has previously been linked to increased Alzheimer's risk in larger genetic studies, providing a clearer understanding of its connection.
The implications of this research are significant, as it suggests that ImP could become a target for Alzheimer's prevention strategies. However, simply reducing ImP through dietary changes may be challenging. ImP is produced when gut bacteria metabolize histidine, an essential amino acid present in many protein-rich foods. Bendlin emphasized that while improving one's diet is generally beneficial, it is not as simple as eliminating specific foods like eggs or red meat, as histidine is widely found in various foods.
The researchers propose that their discovery could lead to the development of treatments aimed at specifically lowering ImP levels in the bloodstream. Identifying a specific molecule and its associated genetic variation provides a more precise target for further investigation. Bendlin likened this potential approach to cholesterol management, where individuals with elevated cholesterol levels may take medications to reduce their risk of heart disease. If effective inhibitors for ImP can be developed, they could potentially reduce the risk of Alzheimer's and slow cognitive decline for many individuals. This study involved contributions from scientists at the University of California, Los Angeles, and the University of Gothenburg, and was supported by various grants from the Wisconsin Partnership Program and the National Institutes of Health.




